PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1391755
PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1391755
Asia Pacific Multiple Sclerosis Drugs Market, By Disease Type ; By Treatment ; By Drug Type ; By End User ; By Country, Competitive Landscape & Forecast, 2019-2029
Asia-Pacific Multiple Sclerosis Drugs Market Size Expands at Significant CAGR of 8.65% to Reach USD 6.72 Billion by 2029.
Asia-Pacific multiple sclerosis drugs market is flourishing due to the increasing incidence of multiple sclerosis (MS) in the region, growing awareness about MS, advances in treatment options, expanding healthcare infrastructure, and rising healthcare expenditure.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Asia-Pacific multiple sclerosis drugs market size at USD 4.09 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the Asia-Pacific multiple sclerosis drugs market size to grow at a significant CAGR of 8.65% reaching a value of USD 6.72 billion by 2029. Asia-Pacific multiple sclerosis drugs market is influenced by several key factors. A rising incidence of multiple sclerosis in the region drives market growth. Also, increased awareness and early diagnosis contribute to higher demand for MS drugs. Advancements in healthcare infrastructure expanded access to healthcare services, and government initiatives supporting neurology research and treatment further boosted the market. Collaboration between pharmaceutical companies and research institutions fosters innovation in drug development. Further, the growing aging population and changing lifestyles increase the patient pool, creating a sustained demand for multiple sclerosis drugs in the Asia-Pacific region.
Multiple Sclerosis Drugs - Overview
Multiple sclerosis (MS) drugs aim to manage the chronic autoimmune disease that affects the central nervous system. They fall into several categories, including disease-modifying therapies (DMTs), which slow the progression of MS and reduce relapses. Common DMTs include interferons, oral medications like fingolimod, and monoclonal antibodies such as ocrelizumab. Symptomatic treatments alleviate specific MS symptoms, like muscle spasms and fatigue. These drugs can improve a patient's quality of life but do not alter the course of the disease. A comprehensive approach to MS management typically combines DMTs and symptomatic treatments, tailored to each patient's specific needs and disease progression.
Impact of COVID-19 on Asia-Pacific Multiple Sclerosis Drugs Market
Asia-Pacific multiple sclerosis drugs market significantly shifts due to the COVID-19 pandemic. The market faced disruptions in supply chains, delayed clinical trials, and altered patient care dynamics, impacting drug availability and treatment continuity. Telemedicine and home-based treatments gained prominence, while healthcare systems adapted to new safety measures. Despite these challenges, the market showed resilience, with increased research and development efforts to address the unique needs of multiple sclerosis patients in the Asia-Pacific region. The pandemic underscored the importance of adaptable healthcare strategies and accelerated digital transformations in the industry.
Asia-Pacific Multiple Sclerosis Drugs Market - By Treatment
By treatment, Asia-Pacific multiple sclerosis drugs market is divided into Preventive Therapies, Abortive Therapies/Treatment of Acute Exacerbations, and Symptomatic Therapies segments. Preventive Therapies constitute the largest treatment segment. Preventive Therapies are aimed at reducing the frequency and severity of multiple sclerosis (MS) relapses, making them a pivotal component of managing the disease. They include disease-modifying drugs that work to slow down the progression of MS and reduce inflammation. This segment's prominence reflects the growing importance of long-term management and the need to prevent MS exacerbations, ultimately improving the quality of life for patients in the Asia-Pacific region.
Competitive Landscape
Asia-Pacific multiple sclerosis drugs market is fiercely competitive. Major companies in the market include Biogen, Sanofi, Novartis, Mitsubishi Tanabe Pharma, Merck Group, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries, Sawai Pharmaceutical Co., Ltd, Meiji Seika Pharma Co., Ltd, and LG Chem Life Sciences. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Asia-Pacific multiple sclerosis drugs market.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Asia-Pacific Multiple Sclerosis Drugs Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technology trends in Asia-Pacific Multiple Sclerosis Drugs Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
Table of Contents
1. Research Framework
- 1.1. Research Objective
- 1.2. Product Overview
- 1.3. Market Segmentation
2. Executive Summary
3. Asia-Pacific Multiple Sclerosis Drugs Market Insights
- 3.1. Industry Value Chain Analysis
- 3.2. DROC Analysis
- 3.2.1. Growth Drivers
- 3.2.1.1. Increasing awareness about multiple sclerosis
- 3.2.1.2. Increasing number of prospective pipeline drug development projects
- 3.2.2. Restraints
- 3.2.2.1. High treatment expenditure
- 3.2.2.2. Limited access to high-cost therapies
- 3.2.3. Opportunity
- 3.2.3.1. Increasing demand of branded drugs
- 3.2.3.2. Rapid advancements in the healthcare industry
- 3.2.4. Challenges
- 3.2.4.1. Lack of diagnosis and awareness
- 3.2.1. Growth Drivers
- 3.3. Technological Advancements/Recent Developments
- 3.4. Regulatory Framework
- 3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry
4. Asia-Pacific Multiple Sclerosis Drugs Market Overview
- 4.1. Market Size & Forecast by Value & Volume, 2019-2029
- 4.1.1. By Value (USD Million)
- 4.2. Market Share & Forecast
- 4.2.1. By Disease Type
- 4.2.1.1. Relapsing-Remitting Multiple Sclerosis (RRMS)
- 4.2.1.2. Secondary Progressive Multiple Sclerosis (SPMS)
- 4.2.1.3. Primary Progressive Multiple Sclerosis (PPMS)
- 4.2.1.4. Severe Relapsing-Remitting Multiple Sclerosis (RES)
- 4.2.2. By Treatment
- 4.2.2.1. Preventive Therapies
- 4.2.2.2. Abortive Therapies/Treatment of Acute Exacerbations
- 4.2.2.3. Symptomatic Therapies
- 4.2.3. By Drug Type
- 4.2.3.1. Branded
- 4.2.3.2. Generic
- 4.2.4. By End User
- 4.2.4.1. Hospital and Clinics
- 4.2.4.2. Diagnostic Laboratories
- 4.2.4.3. Others
- 4.2.5. By Country
- 4.2.5.1. China
- 4.2.5.2. India
- 4.2.5.3. Japan
- 4.2.5.4. South Korea
- 4.2.5.5. Australia & New Zealand
- 4.2.5.6. Indonesia
- 4.2.5.7. Malaysia
- 4.2.5.8. Singapore
- 4.2.5.9. Vietnam
- 4.2.5.10. Rest of APAC
- 4.2.1. By Disease Type
5. China Multiple Sclerosis Drugs Market Overview
- 5.1. Market Size & Forecast by Value & Volume, 2019-2029
- 5.1.1. By Value (USD Million)
- 5.2. Market Share & Forecast
- 5.2.1. By Disease Type
- 5.2.2. By Treatment
- 5.2.3. By Drug Type
- 5.2.4. By End User
6. India Multiple Sclerosis Drugs Market Overview
- 6.1. Market Size & Forecast by Value & Volume, 2019-2029
- 6.1.1. By Value (USD Million)
- 6.2. Market Share & Forecast
- 6.2.1. By Disease Type
- 6.2.2. By Treatment
- 6.2.3. By Drug Type
- 6.2.4. By End User
7. Japan Multiple Sclerosis Drugs Market Overview
- 7.1. Market Size & Forecast by Value & Volume, 2019-2029
- 7.1.1. By Value (USD Million)
- 7.2. Market Share & Forecast
- 7.2.1. By Disease Type
- 7.2.2. By Treatment
- 7.2.3. By Drug Type
- 7.2.4. By End User
8. South Korea Multiple Sclerosis Drugs Market Overview
- 8.1. Market Size & Forecast by Value & Volume, 2019-2029
- 8.1.1. By Value (USD Million)
- 8.2. Market Share & Forecast
- 8.2.1. By Disease Type
- 8.2.2. By Treatment
- 8.2.3. By Drug Type
- 8.2.4. By End User
9. Australia & New Zealand Multiple Sclerosis Drugs Market Overview
- 9.1. Market Size & Forecast by Value & Volume, 2019-2029
- 9.1.1. By Value (USD Million)
- 9.2. Market Share & Forecast
- 9.2.1. By Disease Type
- 9.2.2. By Treatment
- 9.2.3. By Drug Type
- 9.2.4. By End User
10. Indonesia Multiple Sclerosis Drugs Market Overview
- 10.1. Market Size & Forecast by Value & Volume, 2019-2029
- 10.1.1. By Value (USD Million)
- 10.2. Market Share & Forecast
- 10.2.1. By Disease Type
- 10.2.2. By Treatment
- 10.2.3. By Drug Type
- 10.2.4. By End User
11. Malaysia Multiple Sclerosis Drugs Market Overview
- 11.1. Market Size & Forecast by Value & Volume, 2019-2029
- 11.1.1. By Value (USD Million)
- 11.2. Market Share & Forecast
- 11.2.1. By Disease Type
- 11.2.2. By Treatment
- 11.2.3. By Drug Type
- 11.2.4. By End User
12. Singapore Multiple Sclerosis Drugs Market Overview
- 12.1. Market Size & Forecast by Value & Volume, 2019-2029
- 12.1.1. By Value (USD Million)
- 12.2. Market Share & Forecast
- 12.2.1. By Disease Type
- 12.2.2. By Treatment
- 12.2.3. By Drug Type
- 12.2.4. By End User
13. Vietnam Multiple Sclerosis Drugs Market Overview
- 13.1. Market Size & Forecast by Value & Volume, 2019-2029
- 13.1.1. By Value (USD Million)
- 13.2. Market Share & Forecast
- 13.2.1. By Disease Type
- 13.2.2. By Treatment
- 13.2.3. By Drug Type
- 13.2.4. By End User
14. Rest of APAC Multiple Sclerosis Drugs Market Overview
- 14.1. Market Size & Forecast by Value & Volume, 2019-2029
- 14.1.1. By Value (USD Million)
- 14.2. Market Share & Forecast
- 14.2.1. By Disease Type
- 14.2.2. By Treatment
- 14.2.3. By Drug Type
- 14.2.4. By End User
15. Competitive Landscape
- 15.1. List of Key Players and Their Offerings
- 15.2. Asia-Pacific Multiple Sclerosis Drugs Company Market Share Analysis, 2022
- 15.3. Competitive Benchmarking, By Operating Parameters
- 15.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, etc.)
16. Impact of Covid-19 on Asia-Pacific Multiple Sclerosis Drugs Market
17. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook and SWOT Analysis)
- 17.1. Biogen
- 17.2. Sanof
- 17.3. Novartis
- 17.4. Mitsubishi Tanabe Pharma
- 17.5. Merck Group
- 17.6. Sun Pharmaceutical Industries Ltd
- 17.7. Teva Pharmaceutical Industries
- 17.8. Sawai Pharmaceutical Co., Ltd
- 17.9. Meiji Seika Pharma Co., Ltd
- 17.10. LG Chem Life Sciences
- 17.11. Other Prominent Players
18. Key Strategic Recommendations
19. Research Methodology
- 19.1. Qualitative Research
- 19.1.1. Primary & Secondary Research
- 19.2. Quantitative Research
- 19.3. Market Breakdown & Data Triangulation
- 19.3.1. Secondary Research
- 19.3.2. Primary Research
- 19.4. Breakdown of Primary Research Respondents, By Region
- 19.5. Assumption & Limitation
*Financial information of non-listed companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable
List of Figures
- Figure 1 Asia-Pacific Multiple Sclerosis Drugs Market Segmentation
- Figure 2 Asia-Pacific Multiple Sclerosis Drugs Market Value Chain Analysis
- Figure 3 Company Market Share Analysis, 2022
- Figure 4 Asia-Pacific Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019-2029
- Figure 5 Asia-Pacific Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019-2029
- Figure 6 Asia-Pacific Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019-2029
- Figure 7 Asia-Pacific Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019-2029
- Figure 8 Asia-Pacific Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019-2029
- Figure 9 Asia-Pacific Multiple Sclerosis Drugs Market Share, By Country, By Value, 2019-2029
- Figure 10 China Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019-2029
- Figure 11 China Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019-2029
- Figure 12 China Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019-2029
- Figure 13 China Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019-2029
- Figure 14 China Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019-2029
- Figure 15 India Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019-2029
- Figure 16 India Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019-2029
- Figure 17 India Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019-2029
- Figure 18 India Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019-2029
- Figure 19 India Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019-2029
- Figure 20 Japan Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019-2029
- Figure 21 Japan Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019-2029
- Figure 22 Japan Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019-2029
- Figure 23 Japan Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019-2029
- Figure 24 Japan Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019-2029
- Figure 25 South Korea Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019-2029
- Figure 26 South Korea Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019-2029
- Figure 27 South Korea Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019-2029
- Figure 28 South Korea Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019-2029
- Figure 29 South Korea Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019-2029
- Figure 30 Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019-2029
- Figure 31 Australia & New Zealand Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019-2029
- Figure 32 Australia & New Zealand Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019-2029
- Figure 33 Australia & New Zealand Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019-2029
- Figure 34 Australia & New Zealand Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019-2029
- Figure 35 Indonesia Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019-2029
- Figure 36 Indonesia Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019-2029
- Figure 37 Indonesia Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019-2029
- Figure 38 Indonesia Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019-2029
- Figure 39 Indonesia Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019-2029
- Figure 40 Malaysia Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019-2029
- Figure 41 Malaysia Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019-2029
- Figure 42 Malaysia Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019-2029
- Figure 43 Malaysia Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019-2029
- Figure 44 Malaysia Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019-2029
- Figure 45 Singapore Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019-2029
- Figure 46 Singapore Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019-2029
- Figure 47 Singapore Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019-2029
- Figure 48 Singapore Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019-2029
- Figure 49 Singapore Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019-2029
- Figure 50 Vietnam Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019-2029
- Figure 51 Vietnam Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019-2029
- Figure 52 Vietnam Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019-2029
- Figure 53 Vietnam Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019-2029
- Figure 54 Vietnam Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019-2029
- Figure 55 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Value (USD Billion), 2019-2029
- Figure 56 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By Disease Type, By Value, 2019-2029
- Figure 57 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By Treatment, By Value, 2019-2029
- Figure 58 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By Drug Type, By Value, 2019-2029
- Figure 59 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Share, By End User, By Value, 2019-2029
List of Tables
- Table 1 Asia-Pacific Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019-2029
- Table 2 Asia-Pacific Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019-2029
- Table 3 Asia-Pacific Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019-2029
- Table 4 Asia-Pacific Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019-2029
- Table 5 Asia-Pacific Multiple Sclerosis Drugs Market Size, By Country, By Value, 2019-2029
- Table 6 China Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019-2029
- Table 7 China Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019-2029
- Table 8 China Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019-2029
- Table 9 China Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019-2029
- Table 10 India Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019-2029
- Table 11 India Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019-2029
- Table 12 India Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019-2029
- Table 13 India Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019-2029
- Table 14 Japan Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019-2029
- Table 15 Japan Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019-2029
- Table 16 Japan Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019-2029
- Table 17 Japan Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019-2029
- Table 18 South Korea Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019-2029
- Table 19 South Korea Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019-2029
- Table 20 South Korea Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019-2029
- Table 21 South Korea Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019-2029
- Table 22 Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019-2029
- Table 23 Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019-2029
- Table 24 Australia & New Zealand Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019-2029
- Table 25 Australia & New Zealand Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019-2029
- Table 26 Indonesia Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019-2029
- Table 27 Indonesia Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019-2029
- Table 28 Indonesia Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019-2029
- Table 29 Indonesia Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019-2029
- Table 30 Malaysia Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019-2029
- Table 31 Malaysia Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019-2029
- Table 32 Malaysia Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019-2029
- Table 33 Malaysia Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019-2029
- Table 34 Singapore Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019-2029
- Table 35 Singapore Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019-2029
- Table 36 Singapore Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019-2029
- Table 37 Singapore Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019-2029
- Table 38 Vietnam Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019-2029
- Table 39 Vietnam Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019-2029
- Table 40 Vietnam Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019-2029
- Table 41 Vietnam Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019-2029
- Table 42 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Disease Type, By Value, 2019-2029
- Table 43 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Treatment, By Value, 2019-2029
- Table 44 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By Drug Type, By Value, 2019-2029
- Table 45 Rest of Asia-Pacific Multiple Sclerosis Drugs Market Size, By End User, By Value, 2019-2029
- Table 47 Biogen Company Overview
- Table 48 Biogen Financial Overview
- Table 49 Sanof Company Overview
- Table 50 Sanof Financial Overview
- Table 51 Novartis Company Overview
- Table 52 Novartis Financial Overview
- Table 53 Mitsubishi Tanabe Pharma Company Overview
- Table 54 Mitsubishi Tanabe Pharma Financial Overview
- Table 55 Merck Group Company Overview
- Table 56 Merck Group Financial Overview
- Table 57 Sun Pharmaceutical Industries Ltd Company Overview
- Table 58 Sun Pharmaceutical Industries Ltd Financial Overview
- Table 59 Teva Pharmaceutical Industries Company Overview
- Table 60 Teva Pharmaceutical Industries Financial Overview
- Table 61 Sawai Pharmaceutical Co., Ltd Company Overview
- Table 62 Sawai Pharmaceutical Co., Ltd Financial Overview
- Table 63 Meiji Seika Pharma Co., Ltd Company Overview
- Table 64 Meiji Seika Pharma Co., Ltd Financial Overview
- Table 65 LG Chem Life Sciences Company Overview
- Table 66 LG Chem Life Sciences Financial Overview
